We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLandos Biopharma Inc

Landos Biopharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-07-24T15:01:22.140986Z
Market Cap
71.68M

Momentum Score

…

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
2.50
Low
22.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
18.00M
Debt / Equity
-
ROE
-70.67%
Net Debt
-37.55M
ROCE
-129.40%
Diluted EPS TTM
-4.00

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -39.28M -38.42M -30.14M -13.47M -6.04M
Net income -37.99M -38.23M -30.14M -13.93M -6.04M
Selling general administrative 14.88M 15.25M 5.34M 1.48M 1.14M
Gross profit - 18.00M - - -
Reconciled depreciation 0.58M 0.20M 0.14M 0.10M 0.08M
Ebit -41.14M -39.01M -30.68M -13.29M -5.93M
Ebitda -40.56M -38.82M -30.08M -13.03M -5.85M
Depreciation and amortization 0.58M 0.20M 0.59M 0.26M 0.08M
Operating income -40.56M -38.82M -30.68M -13.29M -7.94M
Other operating expenses 40.56M 56.82M 30.68M 13.29M 7.94M
Interest expense -0.58M 0.41M 0.46M 0.30M 0.00M
Interest income 1.26M 0.41M 0.46M - -
Net interest income 1.26M 0.41M 0.46M -0.30M -0.00M
Income tax expense -1.28M -0.20M -0.08M 0.46M 1.90M
Total revenue 0.00M 18.00M 0.00M 0.00M 0.00M
Total operating expenses 40.56M 56.82M 30.68M 13.29M 7.94M
Total other income expense net 1.28M 0.39M 0.53M -0.18M 1.90M
Net income from continuing ops -39.28M -38.42M -30.14M -13.47M -6.04M
Net income applicable to common shares - -38.42M -30.14M -13.47M -6.04M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 38.04M 45.25M 92.88M 30.33M 50.48M
Other current assets 0.49M 0.85M 1.27M 0.20M 0.14M
Total liab 6.25M 6.12M 16.61M 84.35M 76.06M
Total stockholder equity 31.79M 39.13M 76.27M -54.02M -25.58M
Deferred long term liab - - - - 0.01M
Other current liab 4.87M 2.69M 3.70M 2.43M 0.98M
Common stock 0.03M 0.40M 0.40M 0.07M 0.06M
Capital stock 0.03M 0.40M 0.40M 0.07M 0.06M
Retained earnings -155.36M -133.43M -94.15M -55.73M -25.59M
Other liab - - - 0.28M -
Other assets - - 0.03M - 0.01M
Cash 37.55M 36.64M 8.30M 2.42M 9.81M
Total current liabilities 6.25M 6.12M 16.61M 11.03M 3.03M
Net debt -37.55M -36.64M -8.30M -2.42M -9.81M
Other stockholder equity 187.12M 172.21M 77.36M -71.40M 0.02M
Property plant equipment - - 0.71M 0.44M 0.36M
Total current assets 38.04M 45.25M 92.15M 29.89M 50.11M
Net tangible assets - - 76.27M -54.02M -25.58M
Short term investments 0.00M 7.76M 82.58M 25.72M 40.16M
Net receivables - - - 0.15M 0.00M
Inventory - - - 1.40M -
Accounts payable 1.38M 3.44M 12.91M 8.61M 2.05M
Accumulated other comprehensive income - -0.06M -0.23M 0.01M -0.08M
Common stock total equity - - - 0.07M 0.06M
Non currrent assets other - - 0.03M 25.72M 0.01M
Non current assets total 0.00M 0.00M 0.73M 0.44M 0.37M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 74.06M -58.27M 14.31M -40.17M -40.17M
Change to liabilities - 4.26M 6.51M 0.41M 1.00M
Total cashflows from investing activities - -58.71M 14.13M -40.33M -0.04M
Net borrowings - - - 8.00M 8.00M
Total cash from financing activities 0.00M 91.61M 1.52M 59.65M 5.00M
Change to operating activities - 1.63M -0.64M 2.86M -2.30M
Net income -39.28M -38.42M -30.14M -13.47M -6.04M
Change in cash 28.34M 5.89M -7.39M 9.45M -1.94M
Begin period cash flow 8.30M 2.42M 9.81M 0.36M 2.30M
End period cash flow 36.64M 8.30M 2.42M 9.81M 0.36M
Total cash from operating activities -45.77M -27.06M -22.96M -9.87M -6.90M
Issuance of capital stock 0.00M 93.00M 0.00M 51.67M 5.00M
Depreciation 0.58M 0.20M 0.14M 0.10M 0.08M
Other cashflows from financing activities 74.06M -1.39M 1.52M -40.33M 5.00M
Change to netincome - 5.27M 1.17M 0.21M 0.37M
Capital expenditures 0.01M 0.44M 0.18M 0.16M 0.04M
Change in working capital -10.07M 5.89M 5.87M 3.28M -1.30M
Stock based compensation 1.97M 4.12M 0.83M - -
Other non cash items 1.03M 1.16M 0.05M 0.21M 0.37M
Free cash flow -45.78M -27.50M -23.14M -10.03M -6.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Landos Biopharma Inc

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.

1800 Kraft Drive, Blacksburg, VA, United States, 24060

540 218 1767

https://landosbiopharma.com

19

Name Title Year Born
Mr. Timothy M. Mayleben M.B.A. Principal Financial Officer & Director 1961
Dr. Josep Bassaganya-Riera DVM, Ph.D. Advisor 1975
Mr. Gregory Oakes Pres, CEO & Director 1968
Mr. Patrick Truesdell Principal Accounting Officer 1981
Dr. Fabio Cataldi M.D. Chief Medical Officer NA
Mr. Gregory Oakes President, CEO & Director 1968
Dr. Fabio Cataldi M.D. Executive VP & Chief Medical Officer 1967
Ms. Jennifer Creel Interim Chief Financial Officer 1971
Ms. Rebecca Mosig Ph.D. Vice President of Corporate Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…